We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BioMarin Hits New EMA Obstacle for Hemophilia A Gene Therapy
BioMarin Hits New EMA Obstacle for Hemophilia A Gene Therapy
In another hurdle for BioMarin Pharmaceutical’s investigational hemophilia A gene therapy valoctocogene roxaparvovec, the European Medicines Agency (EMA) has now asked the company to provide a full one-year follow up data from its ongoing phase 3 trial.